Obesity – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Obesity Market Outlook

Thelansis’s “Obesity Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Obesity treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Obesity Overview

Obesity is a metabolic disorder characterized by an excess accumulation of fatty tissue. Its categorization hinges on measuring the body mass index (BMI), a ratio involving a person's weight and height. This calculation helps to categorize health risks tied to obesity within a population. A BMI surpassing 30 kg/m^2 is identified as indicative of obesity, further breaking down into class 1 (30 to 34.9 kg/m^2), class 2 (35 to 39.9 kg/m^2), and class 3 or severe obesity (≥ 40 kg/m^2). Obesity can have significant health implications, increasing the risk of various medical issues, including:

1. Cardiovascular Ailments: Obesity significantly heightens the likelihood of conditions such as heart disease, hypertension, and stroke. Excessive body fat accumulates fatty deposits in arteries, constraining blood flow and elevating the risk of heart-related issues
2. Type 2 Diabetes: A strong association exists between obesity and the onset of type 2 diabetes. Excess fat interferes with the body's ability to utilize insulin, efficiently elevating blood sugar levels
3. Joint Challenges: The surplus weight places added pressure on joints, contributing to osteoarthritis and persistent joint discomfort
4. Respiratory Problems: Obesity can contribute to breathing difficulties, including sleep apnea and obesity hypoventilation syndrome, exacerbating overall well-being
5. Cancer: Specific cancer types, like breast, colon, and pancreatic cancer, have been linked to obesity
6. Mental Well-being: The impact of obesity on mental health and overall wellness is apparent, often inducing issues such as depression, anxiety, and low self-esteem, often due to societal bias and concerns related to body image
7. Liver Disorder: Non-alcoholic fatty liver disease (NAFLD) commonly stems from obesity and can advance to more severe conditions such as non-alcoholic steatohepatitis (NASH) and cirrhosis
8. Reproductive Health: Obesity can lead to hormonal imbalances that negatively affect reproductive health, leading to irregular menstrual cycles, fertility challenges, and complications during pregnancy
9. Kidney Ailments: Obesity is correlated with an escalated risk of kidney disease and eventual kidney failure
10. Gastrointestinal Problems: Obesity contributes to gastroesophageal reflux disease (GERD) and other digestive disorders

Beyond its physical consequences, obesity can erode the quality of life and give rise to psychological issues such as depression and diminished self-esteem. Liraglutide stands as the sole glucagon-like peptide-1 receptor agonist (GLP-1RA) endorsed for treating obesity in individuals without diabetes.

• In the United States, 41.9% of adults and 19.7% of adolescents and children individuals, are afflicted by obesity.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: